Advances in gene therapy for diseases of the eye

Human Gene Therapy

Volumn 27, Issue 8, 2016, Pages 563-579

  Petit, Lolita ^a   Khanna, Hemant ^a   Punzo, Claudio ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MER PROTO ONCOGENE TYROSINE KINASE; PROTEIN; PROTEIN TYROSINE KINASE; RAB ESCORT PROTEIN 1; UNCLASSIFIED DRUG;

ANTIANGIOGENIC GENE THERAPY; CLINICAL TRIAL (TOPIC); EYE DISEASE; GENE REPLACEMENT THERAPY; GENE THERAPY; HUMAN; LEBER CONGENITAL AMAUROSIS; MULTICENTER STUDY (TOPIC); MUTATION; NONHUMAN; OPTOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTO ONCOGENE; RETINA DEGENERATION; RETINA DISEASE; RETINITIS PIGMENTOSA; RETINOPATHY; REVIEW; SECONDARY CONE DEATH; STUDY; VISUAL DISORDER; ANIMAL; EYE DISEASES; GENETICS;

ANIMALS; EYE DISEASES; GENETIC THERAPY; HUMANS;

EID: 84983376107     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.040     Document Type: Review

References (198)

1. Arshavsky VY, Lamb TD, Pugh EN Jr. G proteins and phototransduction. Annu Rev Physiol 2002; 64: 153-187
2. Fishman GA, Jacobson SG, Alexander KR, et al. Outcome measures and their application in clinical trials for retinal degenerative diseases: Outline, review, and perspective. Retina 2005; 25: 772-777
3. Moiseyev G, Chen Y, Takahashi Y, et al. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005; 102: 12413-12418
4. Redmond TM, Poliakov E, Yu S, et al. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A 2005; 102: 13658-13663
5. Zhang T, Enemchukwu NO, Jones A, et al. Genetic deletion of S-opsin prevents rapid cone degeneration in a mouse model of Leber congenital amaurosis. Hum Mol Genet 2015; 24: 1755-1763
6. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 2010; 29: 398-427
7. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-95
8. Narfstrom K, Katz ML, Bragadottir R, et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003; 44: 1663-1672
9. Narfstrom K, Katz ML, Ford M, et al. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered 2003; 94: 31-37
10. Acland GM, Aguirre GD, Bennett J, et al. Longterm restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082
11. Narfstrom K, Vaegan, Katz M, et al. Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 2005; 111: 39-48
12. Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007; 14: 292-303
13. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008; 16: 458-465
14. Annear MJ, Mowat FM, Bartoe JT, et al. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adenoassociated vector expressing RPE65. Hum Gene Ther 2013; 24: 883-893
15. Mowat FM, Breuwer AR, Bartoe JT, et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther 2013; 20: 545-555
16. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A 2013; 110: E517-E525
17. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015; 372: 1887-1897
18. Annear MJ, Bartoe JT, Barker SE, et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther 2011; 18: 53-61
19. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248
20. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239
21. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990
22. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 2015; 372: 1920-1926
23. Pierce EA, Bennett J. The status of RPE65 gene therapy trials: Safety and efficacy. Cold Spring Harb Perspect Med 2015; 5: a017285
24. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology 2016. [Epub ahead of print]
25. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra115
26. Schimmer J, Breazzano S. Investor outlook: Significance of the positive LCA2 gene therapy phase III results. Hum Gene Ther Clin Dev 2015; 26: 208-210
27. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008; 105: 15112-15117
28. Cepko CL, Vandenberghe LH. Retinal gene therapy coming of age. Hum Gene Ther 2013; 24: 242-244
29. Komaromy AM, Rowlan JS, Corr AT, et al. Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther 2013; 21: 1131-1141
30. Ghazi NG, Abboud EB, Nowilaty SR, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: Results of a phase I trial. Hum Genet 2016; 135: 327-343
31. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet 2014; 383: 1129-1137
32. Edwards TL, Jolly JK, Groppe M, et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med 2016; 374: 1996-1998
33. Syed N, Smith JE, John SK, et al. Evaluation of retinal photoreceptors and pigment epithelium in a female carrier of choroideremia. Ophthalmology 2001; 108: 711-720
34. Tolmachova T, Anders R, Abrink M, et al. Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia. J Clin Invest 2006; 116: 386-394
35. Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010; 18: 75-79
36. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 2008; 15: 1311-1320
37. Hasson T, Heintzelman MB, Santos-Sacchi J, et al. Expression in cochlea and retina of myosin VIIa, the gene product defective in Usher syndrome type 1B. Proc Natl Acad Sci U S A 1995; 92: 9815-9819
38. Zallocchi M, Binley K, Lad Y, et al. EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: Development of UshStat. PLoS One 2014; 9: e94272
39. Hashimoto T, Gibbs D, Lillo C, et al. Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Ther 2007; 14: 584-594
40. Gruter O, Kostic C, Crippa SV, et al. Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier. Gene Ther 2005; 12: 942-947
41. Vandenberghe LH, Auricchio A. Novel adenoassociated viral vectors for retinal gene therapy. Gene Ther 2012; 19: 162-168
42. Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007; 81: 11372-11380
43. Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54
44. Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res 2008; 48: 353-359
45. Alexander JJ, Umino Y, Everhart D, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007; 13: 685-687
46. Michalakis S, Muhlfriedel R, Tanimoto N, et al. Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 2010; 18: 2057-2063
47. Pang JJ, Deng WT, Dai X, et al. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One 2012; 7: e35250
48. Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011; 20: 3161-3175
49. Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010; 19: 2581-2593
50. Banin E, Gootwine E, Obolensky A, et al. Gene augmentation therapy restores retinal function and visual behavior in a sheep model of CNGA3 achromatopsia. Mol Ther 2015; 23: 1423-1433
51. Marangoni D, Vijayasarathy C, Bush RA, et al. Intravitreal ciliary neurotrophic factor transiently improves cone-mediated function in a CNGB3-/-mouse model of achromatopsia. Invest Ophthalmol Vis Sci 2015; 56: 6810-6822
52. Langlo C, Dubis A, Michaelides M, et al. CNGB3-achromatopsia clinical trial with CNTF: Diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci 2015; 56: 1505
53. Ye GJ, Budzynski E, Sonnentag P, et al. Conespecific promoters for gene therapy of achromatopsia and other retinal diseases. Hum Gene Ther 2016; 27: 72-82
54. Weber BH, Schrewe H, Molday LL, et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci U S A 2002; 99: 6222-6227
55. Min SH, Molday LL, Seeliger MW, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 2005; 12: 644-651
56. Zeng Y, Takada Y, Kjellstrom S, et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci 2004; 45: 3279-3285
57. Park TK, Wu Z, Kjellstrom S, et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009; 16: 916-926
58. Ou J, Vijayasarathy C, Ziccardi L, et al. Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer. J Clin Invest 2015; 125: 2891-2903
59. Dalkara D, Byrne LC, Klimczak RR, et al. In vivodirected evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013; 5: 189ra176
60. Janssen A, Min SH, Molday LL, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 2008; 16: 1010-1017
61. Den Hollander AI, Black A, Bennett J, et al. Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 2010; 120: 3042-3053
62. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci 2009; 12: 44-52
63. Keeler CE. The inheritance of a retinal abnormality in white mice. Proc Natl Acad Sci U S A 1924; 10: 329-333
64. Blanks JC, Adinolfi AM, Lolley RN. Photoreceptor degeneration and synaptogenesis in retinaldegenerative (rd) mice. J Comp Neurol 1974; 156: 95-106
65. Carter-Dawson LD, LaVail MM, Sidman RL. Differential effect of the rd mutation on rods and cones in the mouse retina. Invest Ophthalmol Vis Sci 1978; 17: 489-498
66. Jimenez AJ, Garcia-Fernandez JM, Gonzalez B, et al. The spatio-temporal pattern of photoreceptor degeneration in the aged rd/rd mouse retina. Cell Tissue Res 1996; 284: 193-202
67. Chang B, Hawes NL, Pardue MT, et al. Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. Vis Res 2007; 47: 624-633
68. Gargini C, Terzibasi E, Mazzoni F, et al. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: A morphological and ERG study. J Comp Neurol 2007; 500: 222-238
69. Davis RJ, Tosi J, Janisch KM, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). Invest Ophthalmol Vis Sci 2008; 49: 5067-5076
70. Aguirre G, Farber D, Lolley R, et al. Retinal degeneration in the dog. III. Abnormal cyclic nucleotide metabolism in rod-cone dysplasia. Exp Eye Res 1982; 35: 625-642
71. Aguirre GD, Rubin LF. Rod-cone dysplasia (progressive retinal atrophy) in Irish setters. J Am Vet Med Assoc 1975; 166: 157-164
72. Goldstein O, Mezey JG, Schweitzer PA, et al. IQCB1 and PDE6B mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds. Invest Ophthalmol Vis Sci 2013; 54: 7005-7019
73. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med 1996; 2: 649-654
74. Kumar-Singh R, Farber DB. Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: Application to the rescue of photoreceptor degeneration. Hum Mol Genet 1998; 7: 1893-1900
75. Takahashi M, Miyoshi H, Verma IM, et al. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol 1999; 73: 7812-7816
76. Jomary C, Vincent KA, Grist J, et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther 1997; 4: 683-690
77. Nishiguchi KM, Carvalho LS, Rizzi M, et al. Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179. Nat Commun 2015; 6: 6006
78. Pang JJ, Boye SL, Kumar A, et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest Ophthalmol Vis Sci 2008; 49: 4278-4283
79. Allocca M, Manfredi A, Iodice C, et al. AAVmediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency. Invest Ophthalmol Vis Sci 2011; 52: 5713-5719
80. Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 2014; 21: 96-105
81. Pang JJ, Dai X, Boye SE, et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 2011; 19: 234-242
82. Petit L, Lheriteau E, Weber M, et al. Restoration of vision in the pde6beta-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther 2012; 20: 2019-2030
83. Pichard V, Provost N, Mendes-Madeira A, et al. AAV-mediated gene therapy halts retinal degeneration in PDE6beta-deficient dogs. Mol Ther 2016
84. Koch SF, Tsai YT, Duong JK, et al. Halting progressive neurodegeneration in advanced retinitis pigmentosa. J Clin Invest 2015; 125: 3704-3713
85. Wert KJ, Davis RJ, Sancho-Pelluz J, et al. Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 2013; 22: 558-567
86. Wert KJ, Sancho-Pelluz J, Tsang SH. Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 2014; 23: 514-523
87. Michalakis S, Koch S, Sothilingam V, et al. Gene therapy restores vision and delays degeneration in the CNGB1 (-/-) mouse model of retinitis pigmentosa. Adv Exp Med Biol 2014; 801: 733-739
88. Palfi A, Chadderton N, O'Reilly M, et al. Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho (-/-) mouse. Mol Ther Methods Clin Dev 2015; 2: 15016
89. Palfi A, Millington-Ward S, Chadderton N, et al. Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 2010; 21: 311-323
90. Khani SC, Pawlyk BS, Bulgakov OV, et al. AAVmediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci 2007; 48: 3954-3961
91. Manfredi A, Marrocco E, Puppo A, et al. Combined rod and cone transduction by adenoassociated virus 2/8. Hum Gene Ther 2013; 24: 982-992
92. Boye SE, Alexander JJ, Boye SL, et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod- And cone-specific expression in the primate retina. Hum Gene Ther 2012; 23: 1101-1115
93. Lheriteau E, Petit L, Weber M, et al. Successful gene therapy in the RPGRIP1-deficient dog: A large model of cone-rod dystrophy. Mol Ther 2014; 22: 265-277
94. Haire SE, Pang J, Boye SL, et al. Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. Invest Ophthalmol Vis Sci 2006; 47: 3745-3753
95. Boye SE, Boye SL, Pang J, et al. Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One 2010; 5: e11306
96. Mihelec M, Pearson RA, Robbie SJ, et al. Longterm preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther 2011; 22: 1179-1190
97. Boye SL, Conlon T, Erger K, et al. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci 2011; 52: 7098-7108
98. Boye SL, Peterson JJ, Choudhury S, et al. Gene therapy fully restores vision to the all-cone Nrl (-/-) Gucy2e (-/-) mouse model of leber congenital amaurosis-1. Hum Gene Ther 2015; 26: 575-592
99. Boye SL, Peshenko IV, Huang WC, et al. AAVmediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther 2013; 24: 189-202
100. Pawlyk BS, Smith AJ, Buch PK, et al. Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 2005; 46: 3039-3045
101. Pawlyk BS, Bulgakov OV, Liu X, et al. Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis. Hum Gene Ther 2010; 21: 993-1004
102. Tan MH, Smith AJ, Pawlyk B, et al. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: Effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet 2009; 18: 2099-2114
103. Sun X, Pawlyk B, Xu X, et al. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 2010; 17: 117-131
104. Ku CA, Chiodo VA, Boye SL, et al. Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Hum Mol Genet 2011; 20: 4569-4581
105. Beltran WA, Cideciyan AV, Iwabe S, et al. Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci U S A 2015; 112: E5844-5853
106. Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A 2012; 109: 2132-2137
107. Trapani I, Banfi S, Simonelli F, et al. Gene therapy of inherited retinal degenerations: Prospects and challenges. Hum Gene Ther 2015; 26: 193-200
108. Boye SE, Boye SL, Lewin AS, et al. A comprehensive review of retinal gene therapy. Mol Ther 2013; 21: 509-519
109. Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vision Res 2015; 111: 124-133
110. Chinskey ND, Besirli CG, Zacks DN. Retinal cell death and current strategies in retinal neuroprotection. Curr Opin Ophthalmol 2014; 25: 228-233
111. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003; 11: 529-541
112. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914-6925
113. Deveraux QL, Takahashi R, Salvesen GS, et al. Xlinked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304
114. Kugler S, Straten G, Kreppel F, et al. The X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo. Cell Death Differ 2000; 7: 815-824
115. Straten G, Schmeer C, Kretz A, et al. Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. Neurobiol Dis 2002; 11: 123-133
116. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther 2002; 5: 780-787
117. Renwick J, Narang MA, Coupland SG, et al. XIAP-mediated neuroprotection in retinal ischemia. Gene Ther 2006; 13: 339-347
118. Petrin D, Baker A, Coupland SG, et al. Structural and functional protection of photoreceptors from MNU-induced retinal degeneration by the Xlinked inhibitor of apoptosis. Invest Ophthalmol Vis Sci 2003; 44: 2757-2763
119. Leonard KC, Petrin D, Coupland SG, et al. XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One 2007; 2: e314
120. Zadro-Lamoureux LA, Zacks DN, Baker AN, et al. XIAP effects on retinal detachment-induced photoreceptor apoptosis [corrected]. Invest Ophthalmol Vis Sci 2009; 50: 1448-1453
121. Ji JZ, Elyaman W, Yip HK, et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: The possible involvement of STAT3 pathway. Eur J Neurosci 2004; 19: 265-272
122. Leaver SG, Cui Q, Plant GW, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther 2006; 13: 1328-1341
123. MacLaren RE, Buch PK, Smith AJ, et al. CNTF gene transfer protects ganglion cells in rat retinae undergoing focal injury and branch vessel occlusion. Exp Eye Res 2006; 83: 1118-1127
124. Maier K, Rau CR, Storch MK, et al. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol 2004; 14: 378-387
125. Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 2194-2200
126. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002; 43: 3292-3298
127. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998; 39: 592-602
128. Chong NH, Alexander RA, Waters L, et al. Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. Invest Ophthalmol Vis Sci 1999; 40: 1298-1305
129. Liang FQ, Dejneka NS, Cohen DR, et al. AAVmediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001; 3: 241-248
130. Lipinski DM, Barnard AR, Singh MS, et al. CNTF gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa. Mol Ther 2015; 23: 1308-1319
131. Schlichtenbrede FC, MacNeil A, Bainbridge JW, et al. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther 2003; 10: 523-527
132. Bok D, Yasumura D, Matthes MT, et al. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002; 74: 719-735
133. Wen R, Song Y, Kjellstrom S, et al. Regulation of rod phototransduction machinery by ciliary neurotrophic factor. J Neurosci 2006; 26: 13523-13530
134. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103: 3896-3901
135. Birch DG, Weleber RG, Duncan JL, et al. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013; 156: 283-292 e281
136. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A 2011; 108: 6241-6245
137. Talcott KE, Ratnam K, Sundquist SM, et al. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 2011; 52: 2219-2226
138. Sullivan T, Rex TS. Systemic gene delivery protects the photoreceptors in the retinal degeneration slow mouse. Neurochem Res 2011; 36: 613-618
139. Colella P, Iodice C, Di Vicino U, et al. Nonerythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration. Hum Mol Genet 2011; 20: 2251-2262
140. Fernandez-Sanchez L, Lax P, Isiegas C, et al. Proinsulin slows retinal degeneration and vision loss in the P23H rat model of retinitis pigmentosa. Hum Gene Ther 2012; 23: 1290-1300
141. Rex TS, Allocca M, Domenici L, et al. Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther 2004; 10: 855-861
142. Punzo C, Xiong W, Cepko CL. Loss of daylight vision in retinal degeneration: Are oxidative stress and metabolic dysregulation to blame? J Biol Chem 2012; 287: 1642-1648
143. Leveillard T, Mohand-Said S, Lorentz O, et al. Identification and characterization of rod-derived cone viability factor. Nat Genet 2004; 36: 755-759
144. Yang Y, Mohand-Said S, Danan A, et al. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther 2009; 17: 787-795
145. Byrne LC, Dalkara D, Luna G, et al. Viralmediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest 2015; 125: 105-116
146. Fridlich R, Delalande F, Jaillard C, et al. The thioredoxin-like protein rod-derived cone viability factor (RdCVFL) interacts with TAU and inhibits its phosphorylation in the retina. Mol Cell Proteomics 2009; 8: 1206-1218
147. Ait-Ali N, Fridlich R, Millet-Puel G, et al. Rodderived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell 2015; 161: 817-832
148. Venkatesh A, Ma S, Le YZ, et al. Activated mTORC1 promotes long-term cone survival in retinitis pigmentosa mice. J Clin Invest 2015; 125: 1446-1458
149. Shen J, Yang X, Dong A, et al. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol 2005; 203: 457-464
150. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007; 213: 809-815
151. Komeima K, Rogers BS, Lu L, et al. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A 2006; 103: 11300-11305
152. Berson EL, Rosner B, Sandberg MA, et al. omega-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2012; 130: 707-711
153. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2010; 128: 403-411
154. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111: 761-772
155. Usui S, Oveson BC, Iwase T, et al. Overexpression of SOD in retina: Need for increase in H (2)O (2)-detoxifying enzyme in same cellular compartment. Free Radic Biol Med 2011
156. Usui S, Komeima K, Lee SY, et al. Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther 2009; 17: 778-786
157. Xiong W, MacColl Garfinkel AE, Li Y, et al. NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest 2015; 125: 1433-1445
158. Petit L, Punzo C. mTORC1 sustains vision in retinitis pigmentosa. Oncotarget 2015; 6: 16786-16787
159. Zieger M, Punzo C. Improved cell metabolism prolongs photoreceptor survival upon retinalpigmented epithelium loss in the sodium iodate induced model of geographic atrophy. Oncotarget 2016; 7
160. Busskamp V, Picaud S, Sahel JA, et al. Optogenetic therapy for retinitis pigmentosa. Gene Ther 2012; 19: 169-175
161. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci 2013; 36: 467-488
162. Deisseroth K. Optogenetics: 10 years of microbial opsins in neuroscience. Nat Neurosci 2015; 18: 1213-1225
163. Lagali PS, Balya D, Awatramani GB, et al. Lightactivated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci 2008; 11: 667-675
164. Doroudchi MM, Greenberg KP, Liu J, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011; 19: 1220-1229
165. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006; 50: 23-33
166. Cronin T, Vandenberghe LH, Hantz P, et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adenoassociated virus capsid and promoter. EMBO Mol Med 2014; 6: 1175-1190
167. Mace E, Caplette R, Marre O, et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol Ther 2015; 23: 7-16
168. Thyagarajan S, van Wyk M, Lehmann K, et al. Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells. J Neurosci 2010; 30: 8745-8758
169. Scalabrino ML, Boye SL, Fransen KM, et al. Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness. Hum Mol Genet 2015; 24: 6229-6239
170. Lu Q, Ganjawala TH, Ivanova E, et al. AAVmediated transduction and targeting of retinal bipolar cells with improved mGluR6 promoters in rodents and primates. Gene Ther 2016
171. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: Safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012; 130: 9-24
172. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010; 329: 413-417
173. Jacobson SG, Sumaroka A, Luo X, et al. Retinal optogenetic therapies: Clinical criteria for candidacy. Clin Genet 2013; 84: 175-182
174. Fehrentz T, Schonberger M, Trauner D. Optochemical genetics. Angew Chem Int Ed Engl 2011; 50: 12156-12182
175. Kramer RH, Fortin DL, Trauner D. New photochemical tools for controlling neuronal activity. Curr Opin Neurobiol 2009; 19: 544-552
176. Specht A, Bolze F, Omran Z, et al. Photochemical tools to study dynamic biological processes. HFSP J 2009; 3: 255-264
177. Volgraf M, Gorostiza P, Numano R, et al. Allosteric control of an ionotropic glutamate receptor with an optical switch. Nat Chem Biol 2006; 2: 47-52
178. Caporale N, Kolstad KD, Lee T, et al. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther 2011; 19: 1212-1219
179. Gaub BM, Berry MH, Holt AE, et al. Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci U S A 2014; 111: E5574-5583
180. Zemelman BV, Lee GA, Ng M, et al. Selective photostimulation of genetically chARGed neurons. Neuron 2002; 33: 15-22
181. Lin B, Koizumi A, Tanaka N, et al. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. Proc Natl Acad Sci U S A 2008; 105: 16009-16014
182. Benarroch EE. The melanopsin system: Phototransduction, projections, functions, and clinical implications. Neurology 2011; 76: 1422-1427
183. Gaub BM, Berry MH, Holt AE, et al. Optogenetic vision restoration using rhodopsin for enhanced sensitivity. Mol Ther 2015; 23: 1562-1571
184. Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: Advances in management and diagnosis. J Clin Med 2015; 4: 343-359
185. Park YG, Roh YJ. New Diagnostic and therapeutic approaches for preventing the progression of diabetic retinopathy. J Diabetes Res 2016; 2016: 1753584
186. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-10709
187. Lai YK, Shen WY, Brankov M, et al. Potential longterm inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 9: 804-813
188. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the bloodretinal barrier. Hum Gene Ther 2003; 14: 129-141
189. Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 2007; 19: 75-79
190. Igarashi T, Miyake K, Masuda I, et al. Adenoassociated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 2010; 21: 631-637
191. Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 2004; 6: 992-1002
192. Tuo J, Pang JJ, Cao X, et al. AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2 (-/-)/Cx3cr1 (-/-) mice. Neurobiol Aging 2012; 33: 433.e1-e10
193. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285: 245-248
194. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490-494
195. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188: 253-263
196. Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001; 3: 186-196
197. Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01- A gene therapy for age-related macular degeneration. Mol Ther 2011; 19: 326-334
198. Rakoczy EP, Lai CM, Magno AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 2015; 386: 2395-2403